The purpose of this study is to understand the safety and effectiveness of infliximab when used in clinical practice. This is a post-marketing surveillance study.
The investigator will record continuously from the first patient since the day of contract to the numbers of patients of contract based on Remicade approval.
Study Type
OBSERVATIONAL
Enrollment
938
Infliximab 5 mg/kg IV given in a schedule according to the official label, based on the indication it is being used for.
To evaluate the safety of Remicade Injection (Infliximab) when used in clinical practice
Time frame: The maximum period for observation in this surveillance would be 30 weeks (6 administrations) for patients with Crohn's disease and 24~30 weeks (6 administrations) for patients with Ankylosing spondylitis.
To evaluate the efficacy of Remicade Injection (Infliximab) when used in clinical practice
Time frame: The maximum period for observation in this surveillance would be 30 weeks (6 administrations) for patients with Crohn's disease and 24~30 weeks (6 administrations) for patients with Ankylosing spondylitis.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.